Notice of Proposed Sale · 144
NovaBridge Biosciences
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- NovaBridge Biosciences
- Issuer CIK
- 0001778016
- SEC file number
- 001-39173
- Phone
- (301) 670 2800
- Person for whose account securities are to be sold
- Cao Sean Wuxiong
- Relationships to issuer
- Officer · CHIEF BUSINESS DEVELOPMENT OFFICER
- Street
- SUITE 400, 2440 RESEARCH BLVD
- City
- ROCKVILLE
- State / country code
- MD
- Postal code
- 20850
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Ordinary Shares | 46,947 | 79,377.99 | 265,377,891 | 09/09/2026 | NASDAQ | CITIGROUP GLOBAL MARKETS |
Broker / market maker — proposed row 1, entry 1
- Name
- CITIGROUP GLOBAL MARKETS
- Street
- 390 GREENWICH ST
- City
- NEW YORK
- State / country code
- NY
- Postal code
- 10013
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Ordinary Shares | 09/03/2026 | RESTRICTED STOCK UNITS VESTING | NOVABRIDGE BIOSCIENCES | 147,554 | N | 09/09/2026 | COMPENSATION |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Remarks
SHARES WERE SOLD TO COVER OBLIGATIONS ARISING FROM THE VESTING AND SETTLEMENT OF EQUITY AWARDS
Notice signature
- Notice date
- 09/09/2026
- Signed
- CONFORMED SIGNATURE ON FILE
Company context
NovaBridge Biosciences ("NovaBridge") (NASDAQ: NBP) is a global biotechnology company advancing a portfolio of therapeutic programs in oncology and ophthalmology. The Company identifies differentiated therapeutic opportunities, generates value-defining clinical evidence, and applies the development, financing and partnering strategy best suited to each program. NovaBridge's portfolio is led by givastomig, a Claudin 18.2 × 4-1BB bispecific antibody being developed for the potential treatment of gastrointestinal malignancies, and Visara, its majority-owned ophthalmology subsidiary. Through Visara, NovaBridge is building a diversified ophthalmology franchise designed to address unmet needs across diseases of the front and back of the eye.